CLINICAL AND ECONOMIC EVALUATION OF ATEZOLIZUMAB + VEMURAFENIB + COBIMETINIB COMBINATION AND NIVOLUMAB + IPILIMUMAB COMBINATION: ADMINISTRATION IN METASTATIC MELANOMA TREATMENT WITH BRAF-CONFIRMED MUTATION IN ADULT PATIENTS

CLINICAL AND ECONOMIC EVALUATION OF ATEZOLIZUMAB + VEMURAFENIB + COBIMETINIB COMBINATION AND NIVOLUMAB + IPILIMUMAB COMBINATION: ADMINISTRATION IN METASTATIC MELANOMA TREATMENT WITH BRAF-CONFIRMED MUTATION IN ADULT PATIENTS

The aim of the study was to conduct a pharmacoeconomic evaluation of the atezolizumab, vemurofenib and cobimetinib (ATZ+VM+COB) combination and the nivolumab and ipilimumab (NIVO+IPI) combination for the treatment of BRAF-confirmed metastatic melanoma in adult patients.Materials and methods. With th...

Full description

Saved in:
Bibliographic Details
Main Authors: I. S. Krysanov, E. V. Makarova, V. Yu. Ermakova
Format: Article
Language:Russian
Published: Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute 2022-07-01
Series:Фармация и фармакология (Пятигорск)
Subjects:
metastatic melanoma
braf mutations
melanoma treatment
“cost-effectiveness” analysis
“budget impact” analysis
atezolizumab
vemurafenib
cobimetinib
Online Access:https://www.pharmpharm.ru/jour/article/view/1120
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items